Table 3 Summary of outcomes of studies of acetylcysteine for prevention of contrast-induced nephropathy.
First Author | Contrast-induced nephropathy* | Acetylcysteine Serum Creatinine (μmol/L) | Control Serum Creatinine (μmol/L) | Dialysis (N) | ||||
|---|---|---|---|---|---|---|---|---|
| Â | Acetylcysteine | Control | Baseline | Second SCr | Baseline | Second SCr | NAC | Control |
Allaqaband 25 | 8/45 (18%) | 6/40 (15%) | 194.5 | 196.3 | 179.5 | 179.5 | 2 | 0 |
Baker 26 | 2/41 (5%) | 8/39 (21%) | 163.6 | 156.5 | 154.7 | 159.1 | 0 | 0 |
Briguori 27 | 6/92 (7%) | 10/91 (11%) | 134.4 | 130.8 | 136.1 | 135.3 | 0 | 1 |
Diaz-Sandoval 28 | 2/25 (8%) | 13/29 (45%) | 146.7 | 135.5 | 137.9 | 166.2 | 0 | 0 |
Durham 29 | 10/38 (26%) | 9/41 (22%) | 194.5 | NR | 203.3 | NR | NR | NR |
Efrati 30 | 0/24 (0%) | 2/25 (8%) | 135.3 | 143.2 | 131.7 | 143.2 | 0 | 0 |
Fung 31 | 8/46 (17%) | 6/45 (13%) | 200.7 | 216.6 | 209.5 | 212.2 | NR | NR |
Goldenberg 32 | 4/41 (10%) | 3/39 (8%) | 176.8 | 176.8 | 168.0 | 165.3 | 0 | 0 |
Kay 33 | 4/102 (4%) | 12/98 (12%) | 119.3 | 107.8 | 120.2 | 122.0 | 0 | 0 |
Kefer 34 | 2/53 (8%) | 3/51 (6%) | 91.9 | 91.1 | 102.5 | 93.7 | 0 | 0 |
MacNeill 35 | 1/21 (5%) | 7/22 (32%) | 167.1 | 168.0 | 168.0 | 210.4 | NR | NR |
Oldemeyer 36 | 4/49 (8%) | 3/47 (6%) | 144.1 | NR | 146.7 | NR | 0 | 0 |
Shyu 37 | 2/60 (3%) | 15/61 (25%) | 247.5 | 221.0 | 247.5 | 274.0 | 0 | 1 |
Vallero 38 | 4/47 (9%) | 4/53 (8%) | 87.5 | 93.7 | 84 | 86.6 | NR | NR |